Drugs that contain Naloxone Hydrochloride; Oxycodone Hydrochloride
1. Targiniq patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7683072 | PURDUE PHARMA LP | Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone |
Mar, 2025
(11 months from now) | |
| US9073933 | PURDUE PHARMA LP | Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone |
Mar, 2025
(11 months from now) | |
| US7674800 | PURDUE PHARMA LP | Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone |
Mar, 2025
(11 months from now) | |
| US9522919 | PURDUE PHARMA LP | Oxycodone compositions |
Mar, 2025
(11 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9205082 | PURDUE PHARMA LP | Opioid agonist/antagonist combinations |
Dec, 2018
(5 years ago) | |
| US8673355 | PURDUE PHARMA LP | Opioid agonist/antagonist combinations |
Dec, 2018
(5 years ago) | |
| US8822487 | PURDUE PHARMA LP | Opioid agonist/opioid antagonist/acetaminophen combinations |
Dec, 2018
(5 years ago) | |
| US9474750 | PURDUE PHARMA LP | Opioid agonist/opioid antagonist/acetaminophen combinations |
Dec, 2018
(5 years ago) | |
| US6696066 | PURDUE PHARMA LP | Opioid agonist/antagonist combinations |
Dec, 2018
(5 years ago) | |
| US6277384 | PURDUE PHARMA LP | Opioid agonist/antagonist combinations |
Dec, 2018
(5 years ago) | |
| US8969369 | PURDUE PHARMA LP | Abuse-resistant controlled-release opioid dosage form |
May, 2022
(1 year, 11 months ago) | |
| US9283216 | PURDUE PHARMA LP | Abuse-resistant controlled-release opioid dosage form |
May, 2022
(1 year, 11 months ago) | |
| US9161937 | PURDUE PHARMA LP | Abuse-resistant controlled-release opioid dosage form |
May, 2022
(1 year, 11 months ago) | |
| US9511066 | PURDUE PHARMA LP | Abuse-resistant controlled-release opioid dosage form |
May, 2022
(1 year, 11 months ago) | |
| US9056051 | PURDUE PHARMA LP | Abuse-resistant controlled-release opioid dosage form |
May, 2022
(1 year, 11 months ago) | |
| US9283221 | PURDUE PHARMA LP | Abuse-resistant controlled-release opioid dosage form |
May, 2022
(1 year, 11 months ago) | |
| US9168252 | PURDUE PHARMA LP | Abuse-resistant controlled-release opioid dosage form |
May, 2022
(1 year, 11 months ago) | |
| US9084729 | PURDUE PHARMA LP | Abuse-resistant controlled-release opioid dosage form |
May, 2022
(1 year, 11 months ago) | |
| US9345701 | PURDUE PHARMA LP | Abuse-resistant controlled-release opioid dosage form |
May, 2022
(1 year, 11 months ago) | |
| US9907793 | PURDUE PHARMA LP | Pharmaceutical preparation containing oxycodone and naloxone |
Apr, 2023
(1 year, 16 days ago) | |
| US8846091 | PURDUE PHARMA LP | Matrix for sustained, invariant and independent release of active compounds |
Apr, 2023
(1 year, 16 days ago) | |
| US8846090 | PURDUE PHARMA LP | Matrix for sustained, invariant and independent release of active compounds |
Apr, 2023
(1 year, 16 days ago) | |
| US9555000 | PURDUE PHARMA LP | Pharmaceutical preparation containing oxycodone and naloxone |
Apr, 2023
(1 year, 16 days ago) | |
| US7674799 | PURDUE PHARMA LP | Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone |
Mar, 2025
(11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Jul 23, 2017 |
Market Authorisation Date: 23 July, 2014
Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate; Management of pain severe enough to require ...
Dosage: TABLET, EXTENDED RELEASE;ORAL
TARGINIQ family patents
